| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CHIR-99021 | GDSC1000 | pan-cancer | AAC | -0.08 | 0.01 |
| mRNA | KHS101 | CTRPv2 | pan-cancer | AAC | 0.088 | 0.01 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.073 | 0.02 |
| mRNA | BMS-708163 | GDSC1000 | pan-cancer | AAC | -0.084 | 0.02 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.11 | 0.02 |
| mRNA | BYL-719 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.02 |
| mRNA | selumetinib:UNC0638 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.081 | 0.02 |
| mRNA | NVP-231 | CTRPv2 | pan-cancer | AAC | 0.075 | 0.02 |
| mRNA | Elesclomol | GDSC1000 | pan-cancer | AAC | -0.083 | 0.02 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | 0.077 | 0.02 |